VIR

Vir Biotechnology Inc

VIR, USA

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

https://www.vir.bio

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VIR
stock
VIR

12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC MarketBeat

Read more →
VIR
stock
VIR

Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com Investing.com Nigeria

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$17.2222

Analyst Picks

Strong Buy

2

Buy

5

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.17

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-20.49 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-16.00 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-69,952.92 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.89% of the total shares of Vir Biotechnology Inc

1.

SB INVESTMENT ADVISERS (UK) LTD

(12.0101%)

since

2025/06/30

2.

BlackRock Inc

(11.628%)

since

2025/06/30

3.

Vanguard Group Inc

(9.5216%)

since

2025/06/30

4.

ARCH VENTURE CORP

(9.2982%)

since

2025/06/30

5.

iShares Core S&P Small-Cap ETF

(3.9731%)

since

2025/08/31

6.

State Street Corp

(3.7826%)

since

2025/06/30

7.

FMR Inc

(2.5617%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.5251%)

since

2025/07/31

9.

Citadel Advisors Llc

(2.4942%)

since

2025/06/30

10.

Dimensional Fund Advisors, Inc.

(2.1653%)

since

2025/06/30

11.

Vanguard Small Cap Index

(1.9327%)

since

2025/07/31

12.

Orbimed Advisors, LLC

(1.7138%)

since

2025/06/30

13.

Geode Capital Management, LLC

(1.6214%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(1.5588%)

since

2025/08/31

15.

Morgan Stanley - Brokerage Accounts

(1.176%)

since

2025/06/30

16.

SPDR® S&P Biotech ETF

(1.1579%)

since

2025/08/31

17.

Vanguard Small Cap Growth Index Inv

(1.0823%)

since

2025/07/31

18.

FIAM Small Cap Core CIT Cl B

(1.0821%)

since

2025/06/30

19.

Charles Schwab Investment Management Inc

(0.9308%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(0.9287%)

since

2025/06/30

21.

Ikarian Capital, LLC

(0.7689%)

since

2025/06/30

22.

Renaissance Technologies Corp

(0.7663%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7378%)

since

2025/07/31

24.

Aberdeen Group PLC

(0.7248%)

since

2025/06/30

25.

Biotech Growth Ord

(0.6793%)

since

2025/05/31

26.

Northern Trust Corp

(0.6682%)

since

2025/06/30

27.

Fidelity Small Cap Index

(0.6438%)

since

2025/06/30

28.

iShares S&P Small-Cap 600 Value ETF

(0.6235%)

since

2025/08/31

29.

Schroder Investment Management Group

(0.605%)

since

2025/06/30

31.

Artisan Partners Limited Partnership

(0.5698%)

since

2025/06/30

32.

iShares Russell 2000 Value ETF

(0.5696%)

since

2025/08/31

33.

VOLORIDGE INVESTMENT MANAGEMENT, LLC

(0.5683%)

since

2025/06/30

34.

DFA US Targeted Value I

(0.5585%)

since

2025/07/31

35.

Vanguard Strategic Equity Inv

(0.5348%)

since

2025/06/30

36.

abrdn Healthcare Investors

(0.5003%)

since

2025/08/31

37.

Vanguard Tax-Managed Small Cap Adm

(0.4195%)

since

2025/07/31

38.

Dimensional US Targeted Value ETF

(0.4096%)

since

2025/08/29

39.

Strategic Advisers Fidelity US TtlStk

(0.3976%)

since

2025/07/31

40.

Artisan International Small-Mid Investor

(0.3949%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.17

EPS Estimate

-0.8407

EPS Difference

-0.3293

Surprise Percent

-39.1697%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.